Donor pretreatment with ProGP-1 abrogates T-cell alloreactivity in vivo.
(A) Survival curves by Kaplan-Meier analysis, pooled from 2 similar experiments. Donor B6 mice were treated as in Figure 3. Splenocytes were harvested on day 11 and control spleen was T-cell–depleted. T cells from control (control allogeneic T, n = 25), G-CSF (G-CSF allogeneic T, n = 12), and ProGP-1 spleen (ProGP-1 allogeneic T, n = 15) were purified and added back in equal numbers (3 × 106) to T-cell–depleted control spleen (7 × 106). T-cell–depleted control spleen (TCD allogeneic, n = 5) was transplanted as a non-GVHD control. These grafts were transplanted into lethally irradiated B6D2F1 recipient mice. Survival, P < .001, G-CSF B6 T cells versus control B6 T cells; P < .0001, G-CSF allogeneic T cells versus ProGP-1 allogeneic T cells. (B) GVHD clinical scores as described in “Materials and methods” were determined as a measure of GVHD severity in surviving animals. *P < .05 between G-CSF T cells and ProGP-1 T cells curves at the time points indicated.
